These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection. Loke WC; Spittle MF; Mitchell S; Kulasegaram R Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908 [TBL] [Abstract][Full Text] [Related]
63. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma. Chew T; Jacobs M Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707 [TBL] [Abstract][Full Text] [Related]
64. [Pulmonary Kaposi's sarcoma in a heterosexual parenteral drug addict patient with the acquired immunodeficiency syndrome]. Grocín AI; Goya MA; Arrizabalaga J; Iribarren JA; Rodríguez-Arrondo F; Tuneu A; Lobo C Med Clin (Barc); 1991 Oct; 97(13):500-2. PubMed ID: 1721989 [TBL] [Abstract][Full Text] [Related]
65. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Gabizon A; Martin F Drugs; 1997; 54 Suppl 4():15-21. PubMed ID: 9361957 [TBL] [Abstract][Full Text] [Related]
66. Liposomal drug targeting in the treatment of Kaposi's sarcoma. Wernz JC AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553 [No Abstract] [Full Text] [Related]
67. Doxorubicin-induced hyperpigmentation. Abbasi NR; Wang N Dermatol Online J; 2008 Oct; 14(10):18. PubMed ID: 19061617 [TBL] [Abstract][Full Text] [Related]
68. DaunoXome approved. AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361607 [No Abstract] [Full Text] [Related]
69. Clearance given for Panretin gel. Oncologist; 1999; 4(2):187. PubMed ID: 10337390 [No Abstract] [Full Text] [Related]
70. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus Caelyx Bhowmik S; Bhowmick S; Maiti K; Chakra A; Shahi P; Rajamannar T Leuk Lymphoma; 2018 Jun; 59(6):1478-1481. PubMed ID: 28994344 [No Abstract] [Full Text] [Related]
71. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution. Bernardi D; Errante D; Stefani M; Salvagno L Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696 [No Abstract] [Full Text] [Related]
73. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Gill PS; Rarick M; McCutchan JA; Slater L; Parker B; Muchmore E; Bernstein-Singer M; Akil B; Espina BM; Krailo M Am J Med; 1991 Apr; 90(4):427-33. PubMed ID: 1707230 [TBL] [Abstract][Full Text] [Related]
74. Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma. Kisseberth WC; MacEwen EG; Helfand SC; Vail DM; London CL; Keller E J Vet Intern Med; 1995; 9(6):425-8. PubMed ID: 8558491 [No Abstract] [Full Text] [Related]
75. Acute reactions in dogs treated with doxorubicin: increased frequency with the use of a generic formulation. Phillips BS; Kraegel SA; Simonson E; Madewell BR J Vet Intern Med; 1998; 12(3):171-2. PubMed ID: 9595378 [TBL] [Abstract][Full Text] [Related]
76. Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain. El-Agamy SE; Abdel-Aziz AK; Esmat A; Azab SS Cancer Chemother Pharmacol; 2019 Jul; 84(1):1-14. PubMed ID: 30955080 [TBL] [Abstract][Full Text] [Related]